Anti-VEGF Treatment of Diabetic Macular Edema in Denmark: Incidence, Burden of Therapy, and Forecasting Analyses
Background: The aim of this study was to analyze demographically stratified incidence rates of patients with diabetic macular edema (DME) commenced in anti-VEGF therapy, to study temporal trends, to report the proportion of patients in active therapy over time, and to develop a model to forecast the...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/13/3/546 |
| _version_ | 1797610695963967488 |
|---|---|
| author | Yousif Subhi Ivan Potapenko Javad Nouri Hajari Morten la Cour |
| author_facet | Yousif Subhi Ivan Potapenko Javad Nouri Hajari Morten la Cour |
| author_sort | Yousif Subhi |
| collection | DOAJ |
| description | Background: The aim of this study was to analyze demographically stratified incidence rates of patients with diabetic macular edema (DME) commenced in anti-VEGF therapy, to study temporal trends, to report the proportion of patients in active therapy over time, and to develop a model to forecast the future number of patients in active treatment. Methods: This was a retrospective registry-based study of all patients with DME who received at least one intravitreal anti-VEGF treatment from 1 January 2007 to 30 June 2022. Population data were extracted from Statistics Denmark. Results: This study included 2220 patients with DME who were commenced in anti-VEGF therapy. Demographic analyses revealed higher incidence rates among males than females and among those aged 60–80 years. The number of patients in active treatment followed an exponential decay curve; hence, this was used to mathematically model the number of patients in active therapy. The number of patients in active treatment is expected to stay relatively stable with a minimal increase until the year 2023. Conclusions: This study provides insight into the practical aspects of the anti-VEGF treatment of DME that allow the planning of adequate health services. |
| first_indexed | 2024-03-11T06:18:50Z |
| format | Article |
| id | doaj.art-13c96504a0234e08bcc4ec712eda0d13 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-11T06:18:50Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-13c96504a0234e08bcc4ec712eda0d132023-11-17T12:03:51ZengMDPI AGJournal of Personalized Medicine2075-44262023-03-0113354610.3390/jpm13030546Anti-VEGF Treatment of Diabetic Macular Edema in Denmark: Incidence, Burden of Therapy, and Forecasting AnalysesYousif Subhi0Ivan Potapenko1Javad Nouri Hajari2Morten la Cour3Department of Clinical Research, University of Southern Denmark, DK-5230 Odense, DenmarkDepartment of Ophthalmology, Rigshospitalet Copenhagen, DK-2600 Glostrup, DenmarkDepartment of Ophthalmology, Rigshospitalet Copenhagen, DK-2600 Glostrup, DenmarkDepartment of Ophthalmology, Rigshospitalet Copenhagen, DK-2600 Glostrup, DenmarkBackground: The aim of this study was to analyze demographically stratified incidence rates of patients with diabetic macular edema (DME) commenced in anti-VEGF therapy, to study temporal trends, to report the proportion of patients in active therapy over time, and to develop a model to forecast the future number of patients in active treatment. Methods: This was a retrospective registry-based study of all patients with DME who received at least one intravitreal anti-VEGF treatment from 1 January 2007 to 30 June 2022. Population data were extracted from Statistics Denmark. Results: This study included 2220 patients with DME who were commenced in anti-VEGF therapy. Demographic analyses revealed higher incidence rates among males than females and among those aged 60–80 years. The number of patients in active treatment followed an exponential decay curve; hence, this was used to mathematically model the number of patients in active therapy. The number of patients in active treatment is expected to stay relatively stable with a minimal increase until the year 2023. Conclusions: This study provides insight into the practical aspects of the anti-VEGF treatment of DME that allow the planning of adequate health services.https://www.mdpi.com/2075-4426/13/3/546diabetic macular edemaanti-VEGFincidenceburden of therapyforecastingDenmark |
| spellingShingle | Yousif Subhi Ivan Potapenko Javad Nouri Hajari Morten la Cour Anti-VEGF Treatment of Diabetic Macular Edema in Denmark: Incidence, Burden of Therapy, and Forecasting Analyses Journal of Personalized Medicine diabetic macular edema anti-VEGF incidence burden of therapy forecasting Denmark |
| title | Anti-VEGF Treatment of Diabetic Macular Edema in Denmark: Incidence, Burden of Therapy, and Forecasting Analyses |
| title_full | Anti-VEGF Treatment of Diabetic Macular Edema in Denmark: Incidence, Burden of Therapy, and Forecasting Analyses |
| title_fullStr | Anti-VEGF Treatment of Diabetic Macular Edema in Denmark: Incidence, Burden of Therapy, and Forecasting Analyses |
| title_full_unstemmed | Anti-VEGF Treatment of Diabetic Macular Edema in Denmark: Incidence, Burden of Therapy, and Forecasting Analyses |
| title_short | Anti-VEGF Treatment of Diabetic Macular Edema in Denmark: Incidence, Burden of Therapy, and Forecasting Analyses |
| title_sort | anti vegf treatment of diabetic macular edema in denmark incidence burden of therapy and forecasting analyses |
| topic | diabetic macular edema anti-VEGF incidence burden of therapy forecasting Denmark |
| url | https://www.mdpi.com/2075-4426/13/3/546 |
| work_keys_str_mv | AT yousifsubhi antivegftreatmentofdiabeticmacularedemaindenmarkincidenceburdenoftherapyandforecastinganalyses AT ivanpotapenko antivegftreatmentofdiabeticmacularedemaindenmarkincidenceburdenoftherapyandforecastinganalyses AT javadnourihajari antivegftreatmentofdiabeticmacularedemaindenmarkincidenceburdenoftherapyandforecastinganalyses AT mortenlacour antivegftreatmentofdiabeticmacularedemaindenmarkincidenceburdenoftherapyandforecastinganalyses |